27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Pfizer Inc (NYSE:PFE) announced overall survival (OS) results from the Phase 3 PALOMA-2 trial of Ibrance (palbociclib) combined with Novartis AG's (NYSE:NVS) Femara (letrozole) in breast cancer setting compared to placebo.
- After a median follow-up of seven and a half years, Ibrance/Femara combo failed to extend the lives of those breast cancer patients compared with Femara alone.
- Patients on the Ibrance-Femara combo lived a median of 53.9 months versus 51.2 months for those in the solo Femara group.
- PALOMA-2 met its primary endpoint of progression-free survival (PFS) in 2016 and was published in The New England Journal of Medicine in November 2016.
- The results demonstrated that Ibrance plus letrozole resulted in an improved median PFS of 24.8 months compared to 14.5 months with placebo plus letrozole (HR=0.580).
- The trial also showed that in addition to substantially delaying progressive disease, Ibrance as a first-line treatment, combined with letrozole, delayed the time to chemotherapy (38.1 months vs. 29.8 months).
- Price Action: PFE shares closed higher by 0.95% at $53.18 on Friday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!